STTK — Shattuck Labs Inc
NASDAQ · Healthcare · Biotechnology
$6.87
-$0.14 (-2.00%)
Shattuck Labs Inc (STTK) is a biotechnology company listed on NASDAQ. It is led by Taylor H. Schreiber M.D., Ph.D., based in 500 West 5th Street, Austin, TX, United States, 78701, with about 40 employees. Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Latest reported STTK revenue for 2025-09-30 was $1.0M. Net income was -$10.1M. STTK currently screens at market cap $351.2M.
Use this STTK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the STTK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the STTK SEC filings page. Lician reads the product cache first so this HTML stays unique to Shattuck Labs Inc even when a live quote feed is slow.
About Shattuck Labs Inc
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
STTK Key Statistics
Market Cap
$351.20M
Volume
868,868
Previous Close
$7.90
Day Range
$7.93 – $8.15
EPS
-$1.49
Revenue
$5.72M
Net Income
-$75.41M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+245.3%
Profit Margin
-1318.1%
Employees
40
STTK Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $5.72M | $1.66M | $652.00K | $30.02M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$75.41M | -$87.30M | -$101.94M | -$44.97M |
| EPS (Diluted) | -$1.49 | -$2.05 | -$2.41 | -$1.07 |
Total Assets
$91.05M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$57.39M
Operating Cash Flow
-$60.52M
Free Cash Flow
$0.00
Shattuck Labs Inc Company Information
- Co-Founder, CEO & Director
- Taylor H. Schreiber M.D., Ph.D.
- Headquarters
- 500 West 5th Street, Austin, TX, United States, 78701
- Website
- www.shattucklabs.com
- Phone
- 512 900 4690
- IPO / Founded
- 2020-10-09
- Sector
- Healthcare
- Industry
- Biotechnology